Literature DB >> 11176917

Osteoporosis prevention, diagnosis, and therapy.

.   

Abstract

OBJECTIVES: To clarify the factors associated with prevention, diagnosis, and treatment of osteoporosis, and to present the most recent information available in these areas. PARTICIPANTS: From March 27-29, 2000, a nonfederal, nonadvocate, 13-member panel was convened, representing the fields of internal medicine, family and community medicine, endocrinology, epidemiology, orthopedic surgery, gerontology, rheumatology, obstetrics and gynecology, preventive medicine, and cell biology. Thirty-two experts from these fields presented data to the panel and an audience of 699. Primary sponsors were the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institutes of Health Office of Medical Applications of Research. EVIDENCE: MEDLINE was searched for January 1995 through December 1999, and a bibliography of 2449 references provided to the panel. Experts prepared abstracts for presentations with relevant literature citations. Scientific evidence was given precedence over anecdotal experience. CONSENSUS PROCESS: The panel, answering predefined questions, developed conclusions based on evidence presented in open forum and the literature. The panel composed a draft statement, which was read and circulated to the experts and the audience for public discussion. The panel resolved conflicts and released a revised statement at the end of the conference. The draft statement was posted on the Web on March 30, 2000, and updated with the panel's final revisions within a few weeks.
CONCLUSIONS: Though prevalent in white postmenopausal women, osteoporosis occurs in all populations and at all ages and has significant physical, psychosocial, and financial consequences. Risks for osteoporosis (reflected by low bone mineral density [BMD]) and for fracture overlap but are not identical. More attention should be paid to skeletal health in persons with conditions associated with secondary osteoporosis. Clinical risk factors have an important but poorly validated role in determining who should have BMD measurement, in assessing fracture risk, and in determining who should be treated. Adequate calcium and vitamin D intake is crucial to develop optimal peak bone mass and to preserve bone mass throughout life. Supplementation with these 2 nutrients may be necessary in persons not achieving recommended dietary intake. Gonadal steroids are important determinants of peak and lifetime bone mass in men, women, and children. Regular exercise, especially resistance and high-impact activities, contributes to development of high peak bone mass and may reduce risk of falls in older persons. Assessment of bone mass, identification of fracture risk, and determination of who should be treated are the optimal goals when evaluating patients for osteoporosis. Fracture prevention is the primary treatment goal for patients with osteoporosis. Several treatments have been shown to reduce the risk of osteoporotic fractures, including those that enhance bone mass and reduce the risk or consequences of falls. Adults with vertebral, rib, hip, or distal forearm fractures should be evaluated for osteoporosis and given appropriate therapy.

Entities:  

Mesh:

Year:  2001        PMID: 11176917     DOI: 10.1001/jama.285.6.785

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  1096 in total

Review 1.  Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis.

Authors:  T Saito; J M Sterbenz; S Malay; L Zhong; M P MacEachern; K C Chung
Journal:  Osteoporos Int       Date:  2017-08-02       Impact factor: 4.507

2.  Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment.

Authors:  Masataka Shiraki; Tatsuhiko Kuroda; Yumiko Shiraki; Shiro Tanaka; Tsuyoshi Higuchi; Mitsuru Saito
Journal:  J Bone Miner Metab       Date:  2010-05-11       Impact factor: 2.626

3.  Lack of evidence for prescription of antepartum bed rest.

Authors:  Judith A Maloni
Journal:  Expert Rev Obstet Gynecol       Date:  2011-07-01

4.  Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study.

Authors:  Masayuki Takakuwa; Jun Iwamoto; Masahisa Konishi; Qi Zhou; Koichi Itabashi
Journal:  J Bone Miner Metab       Date:  2010-06-09       Impact factor: 2.626

5.  The impact of substance abuse on osteoporosis screening and risk of osteoporosis in women with psychotic disorders.

Authors:  D L Kelly; C S Myers; M T Abrams; S Feldman; J Park; R P McMahon; J-C Shim
Journal:  Osteoporos Int       Date:  2010-06-09       Impact factor: 4.507

6.  Hip fractures in users of first- vs. second-generation bisphosphonates.

Authors:  M Mamdani; A Kopp; G Hawker
Journal:  Osteoporos Int       Date:  2007-09-01       Impact factor: 4.507

7.  Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study.

Authors:  Masataka Shiraki; Akira Itabashi
Journal:  J Bone Miner Metab       Date:  2009-01-27       Impact factor: 2.626

8.  WNT3A gene polymorphisms are associated with bone mineral density variation in postmenopausal mestizo women of an urban Mexican population: findings of a pathway-based high-density single nucleotide screening.

Authors:  Rafael Velázquez-Cruz; Humberto García-Ortiz; Manuel Castillejos-López; Manuel Quiterio; Margarita Valdés-Flores; Lorena Orozco; Teresa Villarreal-Molina; Jorge Salmerón
Journal:  Age (Dordr)       Date:  2014-03-03

9.  FRAX calculated without BMD does not correctly identify Caucasian men with densitometric evidence of osteoporosis.

Authors:  R C Hamdy; E Seier; K Whalen; W A Clark; K Hicks; T B Piggee
Journal:  Osteoporos Int       Date:  2018-02-03       Impact factor: 4.507

10.  Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study.

Authors:  T W Weiss; E S Siris; E Barrett-Connor; P D Miller; C A McHorney
Journal:  Osteoporos Int       Date:  2007-06-19       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.